Endpoint Health Inc. has announced a new precision immunology program targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling.
Terns Pharmaceuticals Inc. has patented thyroid hormone receptor β (THRβ) agonists reported to be useful for the treatment of nonalcoholic steatohepatitis.
After two years of talks, privately held Ventus Therapeutics Inc. and Novo Nordisk A/S have signed an exclusive worldwide license deal to commercialize candidates from Ventus’ portfolio of peripherally restricted NLR pyrin domain-containing 3 (NLRP3) inhibitors. Along with Roche Holding AG’s September 2020 acquisition of Inflazome Ltd. and Novartis AG’s buyout of subsidiary IFM Tre in April 2019, this is another step by big players to get into the NLRP3 space.
Sino Biopharmaceutical Ltd. subsidiary Chia Tai-Tianqing Pharmaceutical Group Co. Ltd. has acquired greater China rights to lanifibranor from Inventiva SA in a deal worth up to $307 million.
Convalife (Shanghai) Health Technology Co. Ltd. has presented new thyroid hormone receptor α (TR-α) and (TR-β) agonists reported to be useful for the treatment of nonalcoholic fatty liver disease, obesity, liver fibrosis, type 2 diabetes and hypercholesterolemia.
Sino Biopharmaceutical Ltd. subsidiary Chia Tai-Tianqing Pharmaceutical Group Co. Ltd. has acquired greater China rights to lanifibranor from Inventiva SA in a deal worth up to $307 million. Included in the deal are rights to develop and commercialize the drug in mainland China, Hong Kong, Macao, and Taiwan for the treatment of nonalcoholic steatohepatitis (NASH) and other metabolic diseases.
Aqualung Therapeutics Corp. has been awarded two 3-year National Institutes of Health (NIH) Fast Track awards to support development of ALT-100 (enamptcumab), a humanized monoclonal antibody therapy for the chronic indications of pulmonary arterial hypertension (PAH) and inflammatory bowel disease (IBD).
The May 2014 approval of Takeda Pharmaceutical Co. Ltd.’s Entyvio (vedolizumab) brought welcome news in the form of an important mechanism of action for patients with ulcerative colitis and Crohn’s disease, but also means a burdensome course of administration – 30 minutes’ worth of infusion every six weeks, a drawback that other developers are trying to remedy. Standouts among the up-and-comers are Morphic Holding Inc., with an oral candidate that works through the same mechanism of action as Entyvio, and Protagonist Therapeutics Inc.
Medshine Discovery Inc. has patented new sulfinylpyridine-containing nonreceptor tyrosine-protein kinase TYK2 inhibitors expected to be useful for the treatment of Crohn's disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis and ulcerative colitis.
RSS
